Systematic analysis of tumor-infiltrating immune cells in human endometrial cancer: a retrospective study

Objective: The prognostic effect of tumor-infiltrating immune cells (TIICs) on endometrial cancer (EMC) has not been extensively investigated. In the present study, we systematically analyzed the role of TIICs in EMC development. Methods: Patient data were downloaded from The Cancer Genome Atlas (TCGA). We comprehensively analyzed TIIC population in EMC tissue and their role in EMC progression and prognosis by using a deconvolution algorithm (CIBERSORT) and clinically annotated expression profiles. Results: The proportions of gamma delta T cells, resting NK cells, M1 macrophages, and resting mast cells were significantly different in normal endometrium and EMC tissue. The proportion of CD8+ T cells, resting memory CD4 T cells, and M0 macrophages was reversed middle correlated. The proportion of resting dendritic cells, resting memory CD4 T cells, and T regulatory cells (Tregs) decreased in accordance with the cancer cell differentiation grade (G); the lower proportion of activated dendritic cells and gamma delta T cells and higher proportion of Tregs predicted longer EMC survival time and vice versa. The low proportion of gamma delta T cells indicated better response to therapy. Conclusion: Collectively, our data suggested subtle differences in the cellular composition of TIICs in EMC, and these differences were likely to be important determinants of both prognosis and therapy of EMC.

nonactive cells 18 . CD8+ T cells were middle collelation with the two cells; this indicated the activation of the two cells were associated with CD8+ T cells.

Association of TIICs with EMC cell differentiation grade and EMC invasion and metastasis
An interesting result was that the proportion of resting dendritic cells, resting memory CD4 T cells, and Tregs decreased according to the cancer cell differentiation (G); in contrast, the proportion of memory-activated CD4 T cells and M1 and M2 macrophages increased according to the cancer cell differentiation grade (Figure 3). Resting dendritic cells and resting memory CD4 T cells are usually considered as nonactive immune cells 19 20 , while Tregs were found to inhibit endogenous immune responses against tumors 21 . These immune cells might be involved in EMC carcinogenesis; these cells involved in other cancer development was also reported previously 22 . Memory-activated T cells and M1 and M2 macrophages are usually recognized as active immune cells, and our results showed that these cells also play a role in tumor cell differentiation.
We also analyzed the correction between TIICs and regional lymph node (N) involved, and did not find significant TIICs differences in EMC N0, N1, and N2 (Table S1).

Identification of prognostic subsets of TIICs in different clinical stages of EMC
We assessed whether there was a potential correlation between TIICs and patients' clinical stage (FIGO). It was found that the proportion of Tregs decreased during EMC development ( Figure 4A A diverse range of monocytes in the different EMC stages indicated their multifunctionality in EMC metastasis, but further investigations are required to confirm this speculation.

Subsets of TIICs in pre-and postmenopause patients with EMC
Because female sex hormones are present in different levels in pre-(Pre) and postmenopause (Post) women 28-30 , we assessed whether TIICs were affected by hormones. We found that the proportion of naïve B cells ( Figure 5A) and resting memory CD4 T cells ( Figure 5B) decreased in the Post group. the original authors.
Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . https: //doi.org/10.1101/19003707 doi: medRxiv preprint Because both these cell populations are recognized as nonactive immune cells in cancer 20 31 , the decrease in their proportion might be influenced by hormone levels; this aspect requires further investigation.

Identification of prognostic subsets of TIICs in EMC patients' survival time
We found that a lower proportion of activated dendritic cells ( Figure 6A) and gamma delta T cells ( Figure 6B), and higher T regulatory cells (Tregs) ( Figure 6C) predicted a longer EMC survival time than their opposites. Dendritic cells have the potential to overcome tumor tolerance and induce antitumor immunity when loaded with tumor antigens 32 . Despite high potential in promoting antitumor responses, tumor-associated DCs are largely defective in their functional activity and can contribute to immune suppression in cancer 32 . Our present results showed that a high proportion of activated dendritic cells was associated with poor prognoses of patients with EMC. This finding implied that an effective approach to treat EMC was to decrease the activation of dendritic cells. Because gamma delta T cells have potent cytotoxicity and can produce interferon-γ, they are considered to play a protective role in cancer 33 . Furthermore, these cells were reported to be poor prognostic biomarkers in human breast cancer 34 , and we found a similar property of these cells in EMC. Interestingly, Tregs have been shown to exhibit antitumor properties in the tumor microenvironment 35 . We found that a higher proportion of Tregs could improve EMC prognosis, especially in the first 10 years of follow-up.

Identification of subsets of TIICs in therapy-responding EMC patients
Based on the TCGA patients' clinical data, we found that patients with low gamma delta T cells had more effective responses than the patients with high gamma delta T cells (Figure 7).

Discussion
Recently, CIBERSORT, a computational method for analyzing cell populations, has been used to define the proportion of 22 types of TIICs in tissues 36 . This method is based on the genome transcripts of the 22 types of TIICs, and the results of TIICs were combined with patients' clinical data to systematically analyze the association between the proportion of TIICs and patient characteristics 36 . Thus, this approach could overcome the limitation of traditional immunohistochemistry (IH)-based methods because IH defines cell type mainly on the basis of one or two cell markers.
EMC is a hormone-related cancer 37 . The most common lesions (type 1) are typically hormone sensitive and low stage, and they have an excellent prognosis 37 . Hormones can significantly affect the immune system 38 . Our present study revealed that the proportion of naïve B cells and resting memory CD4 T the original authors.
Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . https://doi.org/10.1101/19003707 doi: medRxiv preprint cells were different in pre-and postmenopause women. Thus, the association between TIICs and hormone levels needs further investigation.
Interestingly, the EMC patients with high gamma delta T cells shown low responders to therapy, and with low gamma delta T cells had longer survival times. This result indicated gamma delta T cells might be a key factor for EMC treatment.
The immunotherapy of cancer has made some significant advances in the past few years, with some favorable results 39 . A recent study showed that a combination of immunomodulation, CARs, and immunotherapy might be the next direction for cancer immunotherapy 40 . In the present study, we indicated potential immune cells as targets for the therapy of EMC on the basis of TCGA datasets.
CIBERSORT was used only to estimate the proportions of TIICs. Each TIIC has multi-subsets, and each of the TIIC subsets has wide functions. The position of TIICs and their interaction with different microenvironments would have different effects 41 . Thus, more studies are needed to completely under

Conflicts of interest
There are no any ethical/legal conflicts involved in the article . Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting

ACKNOWLEDGMENTS
The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . https://doi.org/10.1101/19003707 doi: medRxiv preprint   2  0  1  5  ;  3  5  0  (  6  2  6  3  )  :  9  8  5  -9  0  .  d  o  i  :  1  0  .  1  1  2  6  /  s  c  i  e  n  c  e  .  a  a  c  9  4  0  7  2  8  .  G  r  i  m  a  l  d  i  C  M  ,  J  e  g  a  n  a  t  h  a  n  V  ,  D  i  a  m  o  n  d  B  .  H  o  r  m  o  n  a  l  r  e  g  u  l  a  t  i  o  n  o  f  B  c  e  l  l  d  e  v  e  l  o  p  m  e  n  t  :  1  7  b  e  t  a  -e  s  t  r  a  d  i  o  l  i  m  p  a  i  r  s  n  e  g  a  t  i  v  e  s  e  l  e  c  t  i  o  n  o  f  h  i  g  h  -a  f  f  i  n  i  t  y  D  N  A  -r  e  a  c  t  i  v  e  B  c  e  l  l  s  a  t  m  o  r  e  t  h  a  n  o  n  e  d  e  v  e  l  o  p  m  e  n  t  a  l  c  h  e  c  k  p  o  i  n  t  .  J  I  m  m  u  n  o  l  2  0  0      Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . https://doi.org/10.1101/19003707 doi: medRxiv preprint   Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting The copyright holder has placed this preprint (which was not peer-reviewed) in the Public . https://doi.org/10.1101/19003707 doi: medRxiv preprint